ETOPOSIDE
Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified
University of California, DavisSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
89 Active assets in the Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE University of Washington | Phase 3 | BB |
Ifosfamide University of California, Davis | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | BB |
PREDNISONE TABLETS National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →